Search

Displaying results 1471 - 1480 of 10000 in total
  1. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH)[A176020]. … The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent

    Synonyms: rhIGF-I/rhIGFBP-3, Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3
  2. Drug

    Dinoprost

    go.drugbank.com/drugs/DB12789
    ApprovedWithdrawn

    Dinoprost has been investigated in Headache.

    Categories: Prostaglandins F
  3. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    It has been investigated for use in numerous B cell-dependent conditions, including chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and relapsing multiple sclerosis. … CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.

    Categories: Leukemia, Lymphocytic, Chronic, B-Cell, drug therapy
  4. Drug

    Curcuma xanthorrhiza oil

    go.drugbank.com/drugs/DB11265
    ApprovedNutraceutical

    For centuries, _Curcuma xanthorrhiza_ oil has been used as a traditional medicine due to its antibacterial, antispasmodic, antioxidative, antitumor, anti-inflammatory and protective effects [A33160]. … _Curcuma xanthorrhiza_ oil is comprised of 1-2% of curcumin and 3-12% volatile oil, which mainly contains sesquiterpenes, 44.5% of xanthorrhizol, and a small amount of [DB01744] [F114].

  5. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis ( … Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR).

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, Cytochrome P-450 Substrates
  6. Drug

    Artemether

    go.drugbank.com/drugs/DB06697
    ApprovedInvestigational

    </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas. … This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.

    Mixtures: KOMEFAN ® 280, ARTEMETERO Y LUMEFANTRINACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inducers
  7. Drug

    Propoxycaine

    go.drugbank.com/drugs/DB09342
    Approved

    Propoxycaine is a local anesthetic of the ester type that has a rapid onset of action and a longer duration of action than procaine hydrochloride [L1588].

  8. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … [A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers.

    Categories: MATE 1 Inhibitors, P-glycoprotein inhibitorsSynonyms: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
  9. Drug

    Fenoprofen

    go.drugbank.com/drugs/DB00573
    Approved

    An anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.

    Synonyms: 2-(3-phenoxyphenyl)propionic acid, 2-(m-phenoxyphenyl)propionic acidCategories: Non COX-2 selective NSAIDS
  10. Drug

    Sulfasalazine

    go.drugbank.com/drugs/DB00795
    ApprovedInvestigational

    [A255582] Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). … [L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine.

    Categories: Non COX-2 selective NSAIDSSynonyms: 柳氮磺吡啶, 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid